Adi Nosrati
University of California, San Francisco
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Adi Nosrati.
Journal of Clinical Investigation | 2016
Adil Daud; Kimberly Loo; Mariela L. Pauli; Robert Sanchez-Rodriguez; Priscila Munoz Sandoval; Keyon Taravati; Katy K. Tsai; Adi Nosrati; Lorenzo Nardo; Michael Alvarado; Alain Patrick Algazi; Miguel Hernandez Pampaloni; Iryna Lobach; Jimmy Hwang; Robert H. Pierce; Iris K. Gratz; Matthew F. Krummel; Michael D. Rosenblum
BACKGROUND Immune checkpoint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to treatment. The identification of robust biomarkers that predict clinical response to specific checkpoint inhibitors is critical in order to stratify patients and to rationally select combinations in the context of an expanding array of therapeutic options. METHODS We performed multiparameter flow cytometry on freshly isolated metastatic melanoma samples from 2 cohorts of 20 patients each prior to treatment and correlated the subsequent clinical response with the tumor immune phenotype. RESULTS Increasing fractions of programmed cell death 1 high/cytotoxic T lymphocyte-associated protein 4 high (PD-1hiCTLA-4hi) cells within the tumor-infiltrating CD8+ T cell subset strongly correlated with response to therapy (RR) and progression-free survival (PFS). Functional analysis of these cells revealed a partially exhausted T cell phenotype. Assessment of metastatic lesions during anti-PD-1 therapy demonstrated a release of T cell exhaustion, as measured by an accumulation of highly activated CD8+ T cells within tumors, with no effect on Tregs. CONCLUSIONS Our data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy. This information can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition. FUNDING This work was funded by a generous gift provided by Inga-Lill and David Amoroso as well as a generous gift provided by Stephen Juelsgaard and Lori Cook.
Archives of Biochemistry and Biophysics | 2014
Adi Nosrati; Maria L. Wei
Melanoma outcomes differ between men and women even when adjusted for prognostic factors such as age, Breslow thickness, body site, ulceration, lymph node dissection, and for treatment, with men having poorer outcomes compared to women. The mechanisms underlying this disparity are not well understood. Behavioral differences between the sexes such as ultraviolet light exposure and health care services utilization have been suggested as contributing, and differences in endogenous biological processes such as immune function, hormonal regulation, oxidative stress response, vitamin D metabolism and sex chromosome gene expression have also been proposed as mechanisms. This review examines the cumulative evidence for biologically based processes that lead to differences in melanoma biology, including inherent sex-based differences in immune function, oxidative stress response and vitamin D metabolism; the complex interplay between sex hormones, the immune system and oxidative stress response; the effect of non-random X chromosome inactivation on tumorigenesis; and the potential contribution of recently identified oncogenes on the Y chromosome.
Cancer immunology research | 2017
Paul C. Tumeh; Matthew D. Hellmann; Omid Hamid; Katy K. Tsai; Kimberly Loo; Matthew A. Gubens; Michael D. Rosenblum; Christina L. Harview; Janis M. Taube; Nathan Handley; Neharika Khurana; Adi Nosrati; Matthew F. Krummel; Andrew Tucker; Eduardo V. Sosa; Phillip J. Sanchez; Nooriel Banayan; Juan C. Osorio; Dan L. Nguyen-Kim; Jeremy Chang; I. Peter Shintaku; Peter Boasberg; Emma Taylor; Pamela N. Munster; Alain Patrick Algazi; Bartosz Chmielowski; Reinhard Dummer; Tristan Grogan; David Elashoff; Jimmy Hwang
The association between metastatic site and responses to anti-PD-1 immunotherapy was explored In both melanoma and lung cancer. Liver metastasis was associated with worse outcome and CD8+ T cell-poor tumors, suggesting a potential mechanism for the outcomes. We explored the association between liver metastases, tumor CD8+ T-cell count, and response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody, pembrolizumab. The melanoma discovery cohort was drawn from the phase I Keynote 001 trial, whereas the melanoma validation cohort was drawn from Keynote 002, 006, and EAP trials and the non–small cell lung cancer (NSCLC) cohort from Keynote 001. Liver metastasis was associated with reduced response and shortened progression-free survival [PFS; objective response rate (ORR), 30.6%; median PFS, 5.1 months] compared with patients without liver metastasis (ORR, 56.3%; median PFS, 20.1 months) P ≤ 0.0001, and confirmed in the validation cohort (P = 0.0006). The presence of liver metastasis significantly increased the likelihood of progression (OR, 1.852; P < 0.0001). In a subset of biopsied patients (n = 62), liver metastasis was associated with reduced CD8+ T-cell density at the invasive tumor margin (liver metastasis+ group, n = 547 ± 164.8; liver metastasis− group, n = 1,441 ± 250.7; P < 0.016). A reduced response rate and shortened PFS was also observed in NSCLC patients with liver metastasis [median PFS, 1.8 months; 95% confidence interval (CI), 1.4–2.0], compared with those without liver metastasis (n = 119, median PFS, 4.0 months; 95% CI, 2.1–5.1), P = 0.0094. Thus, liver metastatic patients with melanoma or NSCLC that had been treated with pembrolizumab were associated with reduced responses and PFS, and liver metastases were associated with reduced marginal CD8+ T-cell infiltration, providing a potential mechanism for this outcome. Cancer Immunol Res; 5(5); 417–24. ©2017 AACR.
British Journal of Cancer | 2017
Adi Nosrati; Katy K. Tsai; Simone M. Goldinger; Paul C. Tumeh; Barbara Grimes; Kimberly Loo; Alain Patrick Algazi; Thi Dan Linh Nguyen-Kim; Mitchell P. Levesque; Reinhard Dummer; Omid Hamid; Adil Daud
Background:Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a clinical prediction scale for response to anti- PD-1 monotherapy.Methods:A total of 315 patients with advanced melanoma treated with pembrolizumab (2 or 10 mg kg−1 Q2W or Q3W) or nivolumab (3 mg kg−1 Q2W) at four cancer centres between 2011 to 2013 served as the setting for the present cohort study. Variables with significant association to response on a univariate analysis were entered into a forward stepwise logistic regression model and were given a score based on ORs to calculate a clinical prediction scale.Results:The developed clinical prediction scale included elevated LDH (1 point), age <65 years (1 point), female sex (1 point), history of ipilimumab treatment (2 points) and the presence of liver metastasis (2 points). The scale had an area under the receiver-operating curve (AUC) of 0.73 (95% CI 0.67, 0.80) in predicting response to therapy. The predictive performance of the score was maintained in the validation cohort (AUC 0.70 (95% CI 0.58, 0.81)) and the goodness-to-fit model demonstrated good calibration.Conclusions:Based on a large cohort of patients, we developed and validated a simple five-factor prediction scale for the clinical activity of PD-1 antibodies in advanced melanoma patients. This scale can be used to stratify patients participating in clinical trials.
JCI insight | 2017
Kimberly Loo; Katy K. Tsai; Kelly Mahuron; Jacqueline Liu; Mariela L. Pauli; Priscila Munoz Sandoval; Adi Nosrati; James Lee; Lawrence Chen; Jimmy Hwang; Lauren S. Levine; Matthew F. Krummel; Alain Patrick Algazi; Michael Alvarado; Michael D. Rosenblum; Adil Daud
BACKGROUND Programmed death 1 (PD-1) inhibition activates partially exhausted cytotoxic T lymphocytes (peCTLs) and induces tumor regression. We previously showed that the peCTL fraction predicts response to anti-PD-1 monotherapy. Here, we sought to correlate peCTL and regulatory T lymphocyte (Treg) levels with response to combination immunotherapy, and with demographic/disease characteristics, in metastatic melanoma patients. METHODS Pretreatment melanoma samples underwent multiparameter flow cytometric analysis. Patients were treated with anti-PD-1 monotherapy or combination therapy, and responses determined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria. peCTL and Treg levels across demographic/disease variables were compared. Low versus high peCTL (≤20% vs. >20%) were defined from a previous study. RESULTS One hundred and two melanoma patients were identified. The peCTL fraction was higher in responders than nonresponders. Low peCTL correlated with female sex and liver metastasis, but not with lactate dehydrogenase (LDH), tumor stage, or age. While overall response rates (ORRs) to anti-PD-1 monotherapy and combination therapy were similar in high-peCTL patients, low-peCTL patients given combination therapy demonstrated higher ORRs than those who received monotherapy. Treg levels were not associated with these factors nor with response. CONCLUSION In melanoma, pretreatment peCTL fraction is reduced in women and in patients with liver metastasis. In low-peCTL patients, anti-PD-1 combination therapy is associated with significantly higher ORR than anti-PD-1 monotherapy. Fewer tumor-infiltrating peCTLs may be required to achieve response to combination immunotherapy. TRIAL REGISTRATION UCSF IRB Protocol 138510FUNDING. NIH DP2-AR068130, K08-AR062064, AR066821, and Burroughs Wellcome CAMS-1010934 (M.D.R.). Amoroso and Cook Fund, and the Parker Institute for Cancer Immunotherapy (A.I.D.).
JAMA Dermatology | 2017
Adi Nosrati; Jacqueline G. Berliner; Shilpa Goel; Joseph McGuire; Vera Morhenn; Juliana Rocha de Souza; Yıldıray Yeniay; Rasnik Singh; Kristina Lee; Mio Nakamura; Rachel R. Wu; Ann Griffin; Barbara Grimes; Eleni Linos; Mary-Margaret Chren; Roy C. Grekin; Maria L. Wei
Importance Melanoma in situ (MIS) is increasing in incidence, and expert consensus opinion recommends surgical excision for therapeutic management. Currently, wide local excision (WLE) is the standard of care. However, Mohs micrographic surgery (MMS) is now used to treat a growing subset of individuals with MIS. During MMS, unlike WLE, the entire cutaneous surgical margin is evaluated intraoperatively for tumor cells. Objective To assess the outcomes of patients with MIS treated with MMS compared with those treated with WLE. Design, Setting, and Participants Retrospective review of a prospective database. The study cohort consisted of 662 patients with MIS treated with MMS or WLE per standard of care in dermatology and surgery (general surgery, otolaryngology, plastics, oculoplastics, surgical oncology) at an academic tertiary care referral center from January 1, 1978, to December 31, 2013, with follow-up through 2015. Exposure Mohs micrographic surgery or WLE. Main Outcomes and Measures Recurrence, overall survival, and melanoma-specific survival. Results There were 277 patients treated with MMS (mean [SD] age, 64.0 [13.1] years; 62.1% male) and 385 treated with WLE (mean [SD] age, 58.5 [15.6] years; P < .001 for age; 54.8% male). Median follow-up was 8.6 (range, 0.2-37) years. Compared with WLE, MMS was used more frequently on the face (222 [80.2%] vs 141 [36.7%]) and scalp and neck (23 [8.3%] vs 26 [6.8%]; P < .001). The median (range) year of diagnosis was 2008 (1986-2013) for the MMS group vs 2003 (1978-2013) for the WLE group (P < .001). Overall recurrence rates were 5 (1.8%) in the MMS group and 22 (5.7%) in the WLE group (P = .07). Mean (SD) time to recurrence after MMS was 3.91 (4.4) years, and after WLE, 4.45 (2.7) years (P = .73). The 5-year recurrence rate was 1.1% in the MMS group and 4.1% in the WLE group (P = .07). For WLE-treated tumors, the surgical margin taken was greater for tumors that recurred compared with tumors that did not recur (P = .003). Five-year overall survival for MMS was 92% and for WLE was 94% (P = .28). Melanoma-specific mortality for the MMS group was 2 vs 13 patients for the WLE group, with mean (SD) survival of 6.5 (4.8) and 6.1 (0.8) years, respectively (P = .77). Conclusions and Relevance No significant differences were found in the recurrence rate, overall survival, or melanoma-specific survival of patients with MIS treated with MMS compared with WLE.
Pigment Cell & Melanoma Research | 2018
Alain Patrick Algazi; Rosaura Esteve-Puig; Adi Nosrati; Brian R Hinds; Adele Hobbs-Muthukumar; Prachi Nandoskar; Susana Ortiz-Urda; Paul B. Chapman; Adil Daud
Aberrant MAPK and PI3K pathway signaling may drive the malignant phenotype in NRAS‐mutant and BRAFWT NRASWT metastatic melanoma. To target these pathways, NRAS‐mutant and BRAFWT NRASWT patients received oral trametinib at 1.5 mg daily and GSK2141795 at 50 mg daily in a two‐cohort Simon two‐stage design. Participants had adequate end‐organ function and no more than two prior treatment regimens. Imaging assessments were performed at 8‐week intervals. A total of 10 NRAS‐mutant and 10 BRAFWT NRASWT patients were enrolled. No objective responses were noted in either cohort. The median PFS and OS were 2.3 and 4.0 months in the NRAS‐mutant cohort and 2.8 and 3.5 months in the wild‐type cohort. Grade 3 and grade 4 adverse events, primarily rash, were observed in 25% of patients. We conclude that the combination of trametinib and GSK2141795 does not have significant clinical activity in NRAS‐mutant or BRAFWT NRASWT melanoma.
Journal of The American Academy of Dermatology | 2018
Adi Nosrati; Matthew A. Pimentel; A. Falzone; Roshini Hegde; Shilpa Goel; Mary-Margaret Chren; Rachel Eye; Eleni Linos; Sherry L. Pagoto; Barbara J. Walkosz
Patient data, treatment conditions, and clinical and immune responses are shown in Table I. As shown in Fig 1,A, mean values of IL-6, IL-1 , and IL-8 were significantly higher after I-PDT. The data indicated a consistent inflammatory response in patients with BCC treated by I-PDT. We believe that our data provides greater clarity on the role of the immune system during PDT and reveals information about the mechanism of action of the technique. Intravenous ALA plus PDT has been described to induce TNF, IL-10, and IL-6, with IL-6 acting as the key inflammatory cytokine involved in the antitumoral immune response. However, in healthy skin treated with topical ALA plus PDT, TNFhas been described as the driving inflammatory chemotactic factor in inflammationassociated cell dynamics. We did not find any changes in TNFor IL-10 levels. However, IL-1 , IL-8, and IL-6 increased in all patients, suggesting a different inflammatory response pattern. We speculate that different inflammatory mediators might induce different leukocyte migration and differentiation patterns responsible for the longer clinical response with I-PDT, or the clinical response to I-PDT could be related to the increased accumulation of protoporphyrin IX in dormant cancer cells because the injected photosensitizer is able to reach the deepest skin layers. In our study, increased levels of IL-8, IL-1 , and IL-6 were achieved at T1, even before irradiation. In summary, increased IL-1ß, IL-6, and IL-8 levels were achieved after I-PDT. Future research should aim to identify the subsequent immune response stimulated and specific activated cells involved in this process.
Archive | 2018
Adi Nosrati; Maria L. Wei
The incidence of malignant melanoma in most developed countries has risen faster than any other cancer type; In the United States in 2016, women accounted for 39% of the 76,380 new cases of invasive cutaneous melanoma, and only 33% of the 10,130 were melanoma-related deaths. Gender differences in melanoma incidence and outcomes have been consistently observed even when adjusting for prognostic factors such as age, Breslow thickness, body site, ulceration, lymph node dissection, and for treatment. The mechanisms underlying this disparity are not well understood but likely related to both behavioral and biological etiologies. This chapter examines the cumulative evidence for biologically based processes that lead to differences in melanoma biology in men and women, including inherent sex-based differences in immune function, oxidative stress response and vitamin D metabolism; the complex interplay between sex hormones, the immune system and oxidative stress response; the effect of non-random X chromosome inactivation on tumorigenesis; and the potential contribution of recently identified oncogenes on the Y chromosome.
Journal of The American Academy of Dermatology | 2017
Mackenzie R. Wehner; Wilmarie Cidre Serrano; Adi Nosrati; Patrick Schoen; Mary-Margaret Chren; John Boscardin; Eleni Linos
Background: There are varying reports of the association of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) with mortality. Objective: To synthesize the available information on all‐cause mortality after a diagnosis of BCC or SCC in the general population. Methods: We searched PubMed (1966‐present), Web of Science (1898‐present), and Embase (1947‐present) and hand‐searched to identify additional records. All English articles that reported all‐cause mortality in patients with BCC or SCC were eligible. We excluded case reports, case series, and studies in subpopulations of patients. Random effects model meta‐analyses were performed separately for BCC and SCC. Results: The searches yielded 6538 articles, and 156 were assessed in a full‐text review. Twelve studies met the inclusion criteria, and 4 were included in the meta‐analysis (encompassing 464,230 patients with BCC and with 175,849 SCC), yielding summary relative mortalities of 0.92 (95% confidence interval, 0.83‐1.02) in BCC and 1.25 (95% confidence interval, 1.17‐1.32) in SCC. Limitations: Only a minority of studies controlled for comorbidities. There was significant heterogeneity in meta‐analysis (χ2 P < .001, I2 > 98%), but studies of SCC were qualitatively concordant: all showed statistically significant increased relative mortality. Conclusions: We found that patients with SCC are at higher risk for death from any cause compared with the general population.